These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
161 related articles for article (PubMed ID: 33020547)
1. Diurnal stability of cell-free DNA and cell-free RNA in human plasma samples. Wagner JT; Kim HJ; Johnson-Camacho KC; Kelley T; Newell LF; Spellman PT; Ngo TTM Sci Rep; 2020 Oct; 10(1):16456. PubMed ID: 33020547 [TBL] [Abstract][Full Text] [Related]
2. Digital PCR-based evaluation of nucleic acid extraction kit performance for the co-purification of cell-free DNA and RNA. Deleu J; Schoofs K; Decock A; Verniers K; Roelandt S; Denolf A; Verreth J; De Wilde B; Van Maerken T; De Preter K; Vandesompele J Hum Genomics; 2022 Dec; 16(1):73. PubMed ID: 36587211 [TBL] [Abstract][Full Text] [Related]
3. Cell-free DNA and RNA-measurement and applications in clinical diagnostics with focus on metabolic disorders. Drag MH; Kilpeläinen TO Physiol Genomics; 2021 Jan; 53(1):33-46. PubMed ID: 33346689 [TBL] [Abstract][Full Text] [Related]
4. Circulating Cell-Free DNA and RNA Analysis as Liquid Biopsy: Optimal Centrifugation Protocol. Sorber L; Zwaenepoel K; Jacobs J; De Winne K; Goethals S; Reclusa P; Van Casteren K; Augustus E; Lardon F; Roeyen G; Peeters M; Van Meerbeeck J; Rolfo C; Pauwels P Cancers (Basel); 2019 Mar; 11(4):. PubMed ID: 30935089 [TBL] [Abstract][Full Text] [Related]
7. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer. Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961 [TBL] [Abstract][Full Text] [Related]
8. Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer. Fettke H; Kwan EM; Docanto MM; Bukczynska P; Ng N; Graham LK; Mahon K; Hauser C; Tan W; Wang XH; Zhao Z; Zheng T; Zhou K; Du P; Yu J; Huang Y; Jia S; Kohli M; Horvath LG; Azad AA Eur Urol; 2020 Aug; 78(2):173-180. PubMed ID: 32487321 [TBL] [Abstract][Full Text] [Related]
9. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review). Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333 [TBL] [Abstract][Full Text] [Related]
10. Combining cell-free RNA with cell-free DNA in liquid biopsy for hematologic and solid tumors. Albitar M; Zhang H; Charifa A; Ip A; Ma W; McCloskey J; Donato M; Siegel D; Waintraub S; Gutierrez M; Pecora A; Goy A Heliyon; 2023 May; 9(5):e16261. PubMed ID: 37251903 [TBL] [Abstract][Full Text] [Related]
11. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy. Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516 [TBL] [Abstract][Full Text] [Related]
12. Plasma cfDNA as a potential treatment monitoring and prognostic index in patients withnon-small cell lung cancer. Chen N; Li G; Li H; Xiang X; Guo G; Ma Q; Zhang Y Cell Mol Biol (Noisy-le-grand); 2020 Jul; 66(5):208-213. PubMed ID: 33040838 [TBL] [Abstract][Full Text] [Related]
13. Circulating cell-free DNA variables as marker of ovarian cancer patients: A pilot study. Stamenkovic S; Cheng J; Surowy H; Burwinkel B; Gündert M Cancer Biomark; 2020; 28(2):159-167. PubMed ID: 32176629 [TBL] [Abstract][Full Text] [Related]
14. Proof of concept: Detection of cell free RNA from EDTA plasma in patients with lung cancer and non-cancer patients. Mullins KE; Seneviratne C; Shetty AC; Jiang F; Christenson R; Stass S Clin Biochem; 2023 Aug; 118():110583. PubMed ID: 37182637 [TBL] [Abstract][Full Text] [Related]
15. Increased Plasma Circulating Cell-Free DNA Could Be a Potential Marker for Oral Cancer. Lin LH; Chang KW; Kao SY; Cheng HW; Liu CJ Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30352977 [TBL] [Abstract][Full Text] [Related]
16. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients. Yu Z; Qin S; Wang H J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389 [TBL] [Abstract][Full Text] [Related]
17. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC. Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807 [TBL] [Abstract][Full Text] [Related]
18. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden. Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658 [TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsy Based on Cell-Free DNA and RNA. Loy C; Ahmann L; De Vlaminck I; Gu W Annu Rev Biomed Eng; 2024 Jul; 26(1):169-195. PubMed ID: 38346275 [TBL] [Abstract][Full Text] [Related]
20. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]